Saturday 17 October 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.6% and free cash flow grew 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.73
0.00
0.00%
Follow CGTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (83.76%) | (92.82%) | (88.60%) | (109.73%) |
+8 more TTM periods Free account |
|
| (57.33%) | (65.65%) | (59.75%) | (78.86%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(50.93%) | (65.61%) | (68.76%) | (76.91%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.23) | (0.34) | (0.38) | |
Free Cash Flow |
(17.69) | (20.25) | (24.58) | (29.53) | |
Capital Expenditures |
(0.01) | — | 0.01 | — | |
| Other line items | |||||
Cash ROIC |
(26.10%) | (33.13%) | (34.49%) | (38.68%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(2,287.56) | (2,380.06) | (1,911.96) | — | |
Operating CF/Net income |
1.05 | 1.03 | 1.05 | 1.06 | |
Depreciation/Fixed assets |
2.82 | 3.26 | 2.45 | 1.50 | |
Capex/Depreciation |
(0.05) | 0.00 | 0.02 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.23) | (0.34) | (0.38) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | — |
Columns are period end dates